Vantage Secures CMA Category 5 Licence, Strengthening Its MENA Growth Strategy

New UAE regulatory milestone reinforces Vantage's long-term commitment to the region

DUBAI, UAE, July 8, 2026 /PRNewswire/ -- Vantage Markets ("Vantage"), a global multi-asset CFD broker, today announced that it has secured its Capital Market Authority (CMA) Category 5 licence in the United Arab Emirates, marking a significant milestone in the brand's long-term growth strategy across the MENA region.

The regulatory license strengthens Vantage's regional presence in the MENA market. This expansion is a core pillar of Vantage's long-term growth strategy in the Middle East and North Africa. By prioritizing stringent regulatory standards, Vantage seeks to set a benchmark for financial services in the MENA region.

As the UAE continues to accelerate its trajectory as a leading global financial hub, local traders and investors are placing a greater emphasis on the transparency, governance, and security of the platforms they choose. For Vantage, securing this regulatory approval is more than a compliance milestone - it is the bedrock for deeper regional engagement, and meaningful participation in one of the world's most dynamic financial landscapes.

"The UAE is a pivotal market in our global expansion, and securing the CMA Category 5 licence underscores our long-term commitment to the region," said Marc Despallieres, [Global] Chief Executive Officer of Vantage Markets. "As the MENA market continues to mature, traders are looking beyond simple market access. They demand transparency, operational confidence, and responsible support. This milestone allows us to accelerate our growth with market trust at the very center of our approach."

This regulatory achievement arrives as Vantage continues to scale its global footprint through continuous investments in financial technology, product innovation, and comprehensive client education. Across the MENA region, Vantage is dedicated to fostering a highly informed community, seamlessly combining global market access with education-led engagement and a steadfast focus on responsible trading practices.

Vantage's MENA regional strategy is anchored in three core priorities: strengthening local relevance, supporting trader education, and building enduring consumer trust.

With more than 17 years of proven industry experience, Vantage, through the relevant licensed entities, provides global clients with seamless access to contracts for difference (CFDs) across major asset classes - including forex, commodities, indices, shares, and ETFs; all supported by intuitive trading platforms and a client-first ecosystem.

"This is not just a licensing milestone; it is a definitive statement of our long-term intent in the MENA financial market," added Despallieres. "We firmly believe the next chapter of regional growth belongs to firms that effectively combine innovation with regulatory accountability, and that is precisely where Vantage intends to lead."

About Vantage

Vantage Markets is a multi-asset CFD broker offering access to Gold, Forex, Commodities, Indices, Shares, ETFs, and Bonds, offered under the relevant licensed entities under the Vantage Markets brand.

With over 17 years of experience, Vantage provides a reliable trading platform, an award-winning mobile app, and a user-friendly trading experience.

Vantage Global Financial Services L.L.C is licensed by the United Arab Emirates CMA under Category 5, and acts solely as an introducer and not a broker or counterparty to any trades.

Risk Warning: CFDs are complex leveraged products and carry a high risk of losing money rapidly due to leverage. Trading CFDs may not be suitable for all investors. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Disclaimer: This content is for informational purposes only and does not constitute financial or investment advice. Availability of products and services described in this release is subject to jurisdictional restrictions and may not be available to residents of certain countries or regions.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Vantage Secures CMA Category 5 Licence, Strengthening Its MENA Growth Strategy

MONTPELLIER, France, July 8, 2026 /PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company presented its latest advances in AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody development platform at Booth #44.

AI-Enabled Discovery of Highly Selective CLDN18.2 Antibodies

As part of the scientific program, Tsingke presented an AI-enabled workflow for discovering therapeutic antibodies targeting Claudin 18.2 (CLDN18.2), an emerging target for gastric cancer and other solid tumors.

The presentation demonstrated how AI-assisted sequence analysis and a proprietary screening strategy improve target specificity by reducing potential cross-reactivity with the closely related CLDN18.1 protein, a longstanding challenge in CLDN18.2 antibody development.

The resulting antibody candidates showed strong specificity and favorable developability, highlighting the potential of integrating AI with experimental validation to accelerate therapeutic antibody and antibody-drug conjugate (ADC) development.

End-to-End Antibody Development Capabilities

In addition to its scientific presentation, Tsingke showcased its integrated antibody development platform, covering multiple stages of biologics discovery and development, including:

• Antibody Discovery using hybridoma, single B-cell, and phage display technologies for the identification of high-affinity and highly specific antibodies.
• Antibody Engineering including antibody humanization, affinity maturation, and synthetic antibody library construction to accelerate therapeutic antibody optimization.
• Protein Expression supported by six expression systems and a rapid gene-to-protein workflow for applications including monoclonal antibodies, ADCs, AOCs, and in vitro diagnostics (IVD).

"AIS 2026 provided an excellent opportunity to share our latest work in AI-enabled antibody discovery and connect with researchers across the antibody community," said Chuanting Tan, Senior R&D Engineer at Tsingke. "As therapeutic antibody development becomes increasingly complex, integrating computational approaches with experimental validation can help researchers identify and optimize promising candidates more efficiently. We will continue to enhance our discovery and development capabilities to support innovation in biologics research."

Building on these efforts, Tsingke will continue expanding its AI-enabled discovery platform and integrated biologics capabilities to help researchers accelerate projects from early target discovery through protein expression and characterization.

About Tsingke

Tsingke Biotech is a leading innovator in synthetic biology, with a mission to build "the world's great gene factory." Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality Tsynth® gene synthesis services. Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences.

For news and updates, follow Tsingke Biotech on LinkedIn.

Contact: market@tsingke.com.cn 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026